RAPT

RAPT

USD

RAPT Therapeutics Inc. Common Stock

$28.500-0.050 (-0.175%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$28.550

Hoch

$29.605

Tief

$28.190

Volumen

0.43M

Unternehmensfundamentaldaten

Marktkapitalisierung

708.8M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.36M

Börse

NGM

Währung

USD

52-Wochen-Spanne

Tief $5.664Aktuell $28.500Hoch $42.392

Ähnliche Nachrichten

GlobeNewswire

RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing

Mehr anzeigen
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $48 to $72.

Mehr anzeigen
Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72

HC Wainwright & Co. analyst Emily Bodnar maintains RAPT Therapeutics with a Buy and raises the price target from $27 to $72.

Mehr anzeigen
HC Wainwright & Co. Maintains Buy on RAPT Therapeutics, Raises Price Target to $72
Analyst Upgrades

Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70

Guggenheim analyst Yatin Suneja initiates coverage on RAPT Therapeutics with a Buy rating and announces Price Target of $70.

Mehr anzeigen
Guggenheim Initiates Coverage On RAPT Therapeutics with Buy Rating, Announces Price Target of $70
GlobeNewswire

RAPT Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and

Mehr anzeigen
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
Analyst Upgrades

Wells Fargo Maintains Overweight on RAPT Therapeutics, Raises Price Target to $48

Wells Fargo analyst Yanan Zhu maintains RAPT Therapeutics with a Overweight and raises the price target from $38 to $48.

Analyst Upgrades

Barclays Maintains Overweight on RAPT Therapeutics, Raises Price Target to $58

Barclays analyst Etzer Darout maintains RAPT Therapeutics with a Overweight and raises the price target from $35 to $58.